Mathematical Modeling and Optimization Methods for De Novo Protein Design - Systems Biology: Networks, Models, and Applications - page 63

68. Klepeis, J. L., M. T. Pieja and C. A. Floudas. A new class of hybrid global

optimization algorithms for peptide structure prediction: integrated
hybrids. Computer Physics Communications , 151:121-40, 2003.

69. Klepeis, J. L., M. T. Pieja and C. A. Floudas. Hybrid global optimization

algorithms for protein structure prediction: alternating hybrids. Biophysical
Journal , 84:869-82, 2003.

70. Sahu, A., B. K. Kay and J. D. Lambris. Inhibition of human complement by

a C3-binding peptide isolated from a phage displayed random peptide
library. Journal of Immunology , 157:884-91, 1996.

71. Morikis, D., N. Assa-Munt, A. Sahu and J. D. Lambris. Solution structure

of compstatin, a potent complement inhibitor. Protein Science , 7:619-27,
1998.

72. Sahu, A., A. M. Soulika, D. Morikis, L. Spruce, W. T. Moore and

J. D. Lambris. Binding kinetics, structure activity relationship and biotrans-
formation of the complement inhibitor compstatin. Journal of Immunology ,
165:2491-9, 2000.

73. Morikis, D., M. Roy, A. Sahu, A. Torganis, A. Jennings, G. C. Tsokos and

J. D. Lambris. The structural basis of compstatin activity examined by
structure-function-based design of peptide analogs and NMR. Journal of
Biological Chemistry , 277:14942-53, 2002.

74. Soulika, A. M., D. Morikis, M. R. Sarias, M. Roy, L. Spruce, A. Sahu and

J. D. Lambris. Studies of structure-activity relations of complement
inhibitor compstatin. Journal of Immunology , 170:1881-90, 2003.

75. Soulika, A. M., M. M. Khan, T. Hattori, F. W. Bowen, B. A. Richardson,

C. E. Hack, A. Sahu, L. H. Edmunds and J. D. Lambris. Inhibition of
heparin/protamine complex-induced complement activation by compstatin
in baboons. Clinical Immunology , 96:212-21, 2000.

76. Nillson, B., R. Larsson, J. Hong, G. Elgue, K. N. Ekdahl, A. Sahu and

J. D. Lambris. Compstatin inhibits complement and cellular activation in
whole blood in two models of extracorporeal circulation. Blood , 92:1661-7,
1998.

77. Fiane, A. E., T. E. Mollnes, V. Videm, T. Hovig, K. Hogasen, O. J. Mellbye,

L. Spruce, W. T. Moore, A. Sahu and J. D. Lambris. Compstatin, a peptide
inhibitor of C3, prolongs survival of ex-vivo perfused pig xenografts.
Xenotransplantation , 6:52-65, 1999.

78. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth,

V. Videm, K. T. Lappegard, J. Kohl and J. D. Lambris. Essential role of the
C5a receptor in E. coli -induced oxidative burst and phagocytosis revealed
by a novel lepirudin-based human whole blood model of inflammation.
Blood , 100:1869-77, 2002.

79. Klegeris, A., E. A. Singh and P. L. McGeer. Effects of c-reactive protein and

pentosan polysulphate on human complement activation. Immunology ,
106:381-8, 2002.

80. Sahu, A., D. Morikis and J. D. Lambris. Compstatin, a peptide inhibitor of

complement, exhibits species-specific binging to complement component C3.
Molecular Immunology , 39:557-66, 2003.

81. Mallik, B., M. Katragadda, L. A. Spruce, C. Carafides, C. G. Tsokos,

D. Morikis and J. D. Lambris. Design and NMR characterization of active